S100A8 and ulcerative colitis: Previous studies have reported that S100A8-neutralizing antibodies or delivery of S100A8 inhibitors via nanomaterials could attenuate the inflammatory response and enhance the therapeutic efficacy of ulcerative colitis treatment [32, 33].